Novavax, Inc.a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, has been granted full Marketing Authorization by the European Commission

Pheon Therapeutics a leading Antibody-Drug Conjugate specialist developing next generation ADCs for a wide range of hard-to-treat cancers, today announces an exclusive licence agreement

Ascentage Pharma announced today that the company's core product Orebatinib has obtained clinical trial approval from the Center for Drug Evaluation of the National Medical Products

Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration has accepted and granted Priority Review for the company’s Biologics License Application for zolbetuximab

InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the first psoriasis patient has been dosed in clinical trial

Taiho Oncology Europe GmbH and Taiho Pharmaceutical Co., Ltd., announced today that the European Commission has granted conditional marketing authorization for LYTGOBI® monotherapy for the treatment of adult patients with locally advanced or metastatic

Amneal Pharmaceuticals, Inc. today announced the launch of its authorized generic for Xyrem®1 oral solution CIII in the United States. Sodium Oxybate oral solution, 0.5 g/mL is a central nervous

ARUP Laboratories today announced that the U.S. Food and Drug Administration has approved AAV5 DetectCDx™ as a companion diagnostic to aid in the selection of adult patients eligible for treatment with ROCTAVIAN™ (valoctocogene roxaparvovec-rvox). ROCTAVIAN™, a new gene

Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs optimally created spatial conformation nucleic acids that further enhance the drug-like properties

TME Pharma N.V. a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment, announces a positive clinical update on the survival of first-line glioblastoma patients in the GLORIA expansion arm evaluating NOX-A12,